Immediate Impact
43 standout
Citing Papers
Management of Fatigue in Adult Survivors of Cancer: ASCO–Society for Integrative Oncology Guideline Update
2024 Standout
Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522
2024 Standout
Works of Peter Michael Vestlev being referenced
Adjuvant Cyclophosphamide and Docetaxel With or Without Epirubicin for EarlyTOP2A-Normal Breast Cancer: DBCG 07-READ, an Open-Label, Phase III, Randomized Trial
2017
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Peter Michael Vestlev | 109 | 101 | 18 | 38 | 13 | 154 | |
| Benjamin Powers | 106 | 91 | 28 | 34 | 15 | 154 | |
| Paola Di Nardo | 97 | 105 | 27 | 23 | 16 | 189 | |
| B.E. van den Borne | 103 | 99 | 32 | 25 | 10 | 207 | |
| Valérie Lebrun-Ly | 66 | 40 | 13 | 17 | 11 | 142 | |
| D. Perroni | 137 | 40 | 32 | 76 | 10 | 199 | |
| Marta Climent | 144 | 83 | 25 | 45 | 11 | 219 | |
| Ali Abdulnabi Suwaidan | 110 | 49 | 41 | 41 | 13 | 220 | |
| Caroline Pétorin | 148 | 48 | 15 | 41 | 18 | 208 | |
| Abdulla Alhasso | 54 | 122 | 16 | 35 | 15 | 193 | |
| Daniele Alesini | 56 | 119 | 74 | 34 | 18 | 180 |
All Works
Loading papers...